Announcements Trials
Browse Landscape

Status

Active not recruiting 4Withdrawn 2Completed 2Terminated 1Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Amifampridine 4fludarabine phosphate 3gallium 68 PSMA-11 2fludarabine 2carbon-11 acetate 2Whole-Body Irradiation 2Magnetic Resonance Spectroscopy 2Ga(III)-DOTATOC 2Cyclophosphamide 23-Iodobenzylguanidine 2venetoclax 1veliparib 1ulocuplumab 1trametinib 1selinexor 1ponatinib 1pembrolizumab 1pegfilgrastim 1omburtamab I-131 1nirogacestat 1neratinib 1navitoclax 1ganitumab 1gallium Ga 68 dotatate 1fluorodopa F 18 1elotuzumab 1carfilzomib 1asparaginase erwinia chrysanthemi recombinant 1aldesleukin 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × OTHER × navitoclax × Clear all
NCT05215405 2025-02-03

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL

University of Texas Southwestern Medical Center

No longer available
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡